This was based on a significant reduction of lung cancers in the CANTOS trial on 10,061 patients with cardiovascular disorders and high C‐reactive proteins (CRPs) who were randomized to placebo or different doses of canakinumab, an antibody against IL‐1β. Here, IL1B is linked to lung carcinoma.